<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537027</url>
  </required_header>
  <id_info>
    <org_study_id>VitDHiD</org_study_id>
    <nct_id>NCT03537027</nct_id>
  </id_info>
  <brief_title>Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 on Transcriptomic Changes of Low Vitamin D Responders</brief_title>
  <acronym>VitDHiD</acronym>
  <official_title>Comparing the Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 Treatment on Changes of the Transcriptome of Low Vitamin D Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DSM Nutritional Products, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate in vivo whether a high-dose vitamin D3 oral bolus
      (2000 micrograms) produces marked vitamin D receptor target gene expression response and
      whether there is large inter-individual variation. These effects are compared to in vitro
      treatment of peripheral blood mononuclear cells from these subjects with 25(OH)D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum 25-hydroxyvitamin D3 [25(OH)D3] is a well-established marker for vitamin D status of
      the human body. In addition to the general importance of vitamin D for bone health, low serum
      25(OH)D3 concentrations have been associated with increased risk of several health outcomes,
      such as autoimmune diseases, type 2 diabetes and cardiovascular complications. However, there
      is significant inter-individual variation in the average serum 25(OH)D3 concentrations and
      also in the response to supplementation with vitamin D. Genetic and epigenetic factors have
      been suggested to be responsible for a large part of the variation, but currently there is
      little information about the health effects of the variation.

      In our previous studies VitDmet (Clinicaltrials.gov NCT01479933) and VitDbol
      (Clinicaltrials.gov NCT02063334) we showed that the participants can be classified into high,
      mid and low responders to vitamin D and defined the new biomarker &quot;vitamin D response index&quot;.
      Some 25% of the population seem to be low responders and are under higher risk to suffer from
      insufficient supplementation with vitamin D. The current study will focus on low vitamin D
      responders (among the 40 healthy individuals recruited in the study, 20-60 years old), i.e.
      it will use the same oral vitamin D3 bolus (2,000 Âµg, i.e. 80,000 IU in one day) as in our
      VitDbol study, in order to identify low vitamin D responders.

      By in vitro treatment of peripheral blood mononuclear cells (PBMCs) of low responders with
      25(OH)D3 for 24 h (in comparison to in vitro stimulations with 1,25-dihydroxyvitamin D3
      [1,25(OH)2D3] and in vivo vitamin D3 supplementation of the same subjects) we will obtain
      samples that allow the transcriptome-wide investigation of changes in gene expression. The
      underlying hypothesis of this study is that a stimulation with 25(OH)D3 is more efficient
      than a treatment with vitamin D3, so that in future low vitamin D responders may be
      supplemented with 25(OH)D3 rather than with vitamin D3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In vivo change from baseline in vitamin D target gene expression in the subjects</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effect of 2000 microgram vitamin D3 dose on the expression of vitamin D receptor target genes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In vitro change from baseline in vitamin D target gene expression in peripheral blood mononuclear cells</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effects of treatment of cells for 24 h with 100 nM of 25(OH)D3, 1 nM of 1,25(OH)2D3 or vehicle (solvent) on the expression of vitamin D receptor target genes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo change from baseline in serum 25(OH)D concentration</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effect of 2000 microgram vitamin D3 dose on serum 25(OH)D3 concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo change from baseline in serum calcium concentration (safety and tolerability)</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum calcium concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo change from baseline in serum alanine transaminase concentration (safety and tolerability)</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum alanine transaminase (ALAT) concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo change from baseline in serum gamma-glutamyl transferase concentration (safety and tolerability)</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum gamma-glutamyl transferase (GGT) concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In vivo change from baseline in serum creatinine concentration (safety and tolerability)</measure>
    <time_frame>24 hours after the baseline</time_frame>
    <description>Effect of 2000 microgram vitamin D3 dose on in vivo changes in serum creatinine concentrations</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Vitamin D Receptor Target Gene Expression</condition>
  <condition>Serum 25(OH)D Concentration</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 micrograms of vitamin D3 in two doses during one day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking

          -  BMI 20-25 kg/m2.

        Exclusion Criteria:

          -  History of kidney stones, renal failure or dialysis, hypercalcemia, hypo- or
             hyperparathyroidism, severe liver disease (cirrhosis), or sarcoidosis or other
             granulomatous diseases, such as active chronic tuberculosis or Wegener's
             granulomatosis.

          -  Continuous use of anti-inflammatory medicines.

          -  Regular use of supplements containing over 20 micrograms of vitamin D.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Carlberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carsten Carlberg, PhD</last_name>
    <phone>+358-40-3553062</phone>
    <email>carsten.carlberg@uef.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jyrki K Virtanen, PhD</last_name>
    <phone>+358-40-3552957</phone>
    <email>jyrki.virtanen@uef.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Eastern Finland</name>
      <address>
        <city>Kuopio</city>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Carlberg, PhD</last_name>
      <phone>+358-40-3553062</phone>
      <email>carsten.carlberg@uef.fi</email>
    </contact>
    <contact_backup>
      <last_name>Jyrki K Virtanen, PhD</last_name>
      <phone>+358-40-3552957</phone>
      <email>jyrki.virtanen@uef.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Carsten Carlberg, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jyrki K Virtanen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomi-Pekka Tuomainen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Eastern Finland</investigator_affiliation>
    <investigator_full_name>Carsten Carlberg</investigator_full_name>
    <investigator_title>Professor of biochemistry</investigator_title>
  </responsible_party>
  <keyword>vitamin D3</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>calcidiol</keyword>
  <keyword>25-hydroxyvitamin D</keyword>
  <keyword>gene expression</keyword>
  <keyword>vitamin D receptor</keyword>
  <keyword>adults</keyword>
  <keyword>clinical trial</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

